A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia
Phase 3
Completed
- Conditions
- Chronic Kidney DiseaseHyperphosphatemiaDialysis
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2014-09-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 245
- Registration Number
- NCT00506441
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 1015
- Registration Number
- NCT00501046
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 1020
- Registration Number
- NCT00500682
Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes
- First Posted Date
- 2007-07-06
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 183
- Registration Number
- NCT00497198
A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia
Phase 3
Terminated
- Conditions
- Chronic Kidney DiseaseDialysisHyperphosphatemia
- Interventions
- Drug: PlaceboDrug: MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2011-11-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT00451295
Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Phase 3
Completed
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Drug: Placebo of MCI-186
- First Posted Date
- 2007-01-19
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 181
- Registration Number
- NCT00424463
- Locations
- 🇯🇵
National Hospital Organization Miyagi National Hospital, Watari-gun, Miyagi-ken, Japan
A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia
Phase 3
Completed
- Conditions
- HyperphosphatemiaChronic Kidney Disease
- Interventions
- Drug: MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)Drug: PlaceboDrug: Another phosphate binder (Sevelamer)
- First Posted Date
- 2006-12-28
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 336
- Registration Number
- NCT00416520
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) Who Met Severity Classification III
Phase 3
Completed
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Drug: Placebo of MCI-186
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2017-12-20
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT00415519
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 58
- Registration Number
- NCT00412867
- Locations
- 🇯🇵
Investigational site 01, Hokkaido, Japan
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Phase 3
Completed
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- Drug: Placebo of MCI-186
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 206
- Registration Number
- NCT00330681
© Copyright 2025. All Rights Reserved by MedPath